Sai Life Sciences IPO closes today - The Hindu BusinessLine
1 天前 · Private equity major TPG Capital-backed Sai Life Sciences’ initial public offering closes today. The IPO, which was launched with a price band of ₹522-549, was subscribed 1.25 times so far ...
Sai Life Sciences IPO fully subscribed on Day 2; QIBs drive demand
2 天之前 · Sai Life Sciences IPO Subscription status: Rs 3,042 crore public offering of Sai Life Sciences, which opened for subscription yesterday, December 11, 2024, has been fully subscribed on the second day of its subscription.As per data available on the National Stock Exchange (NSE), Sai Life Sciences received consolidated bids for 3,92,14,098 shares against 3,88,29,848 on offer, thus getting ...
Sai Life Sciences CFO sees scope for further margin improvement
3 天之前 · The ₹3,043 crore Initial Public Offering (IPO) of Hyderabad-based Sai Life Sciences, a contract research and manufacturing company, opened for subscription on Wednesday, December 11. In an interview with CNBC-TV18, Managing Director and CEO Krishnam Raju Kanumuri, and CFO Sivaramakrishnan Chittor said that they are their IPO proceeds to ...
Sai Life Sciences IPO: Worth your money? Check GMP, price …
3 天之前 · The Sai Life Sciences IPO comprises a fresh issue of up to 17,304,189 equity shares and an offer for sale (OFS) with promoters and shareholders divesting up to 38,116,934 equity shares, each with a face value of Re 1. Sai Quest Syn is the promoter participating in the OFS. Among other shareholders, TPG Asia VII SF, HBM Private Equity, Bharathi Srivari, Anita Rudraraju Nandyala, Raju Penmasta ...
Sai Life Sciences raises ₹913 crore from anchor investors
3 天之前 · Private equity major TPG Capital-backed Sai Life Sciences on Tuesday collected ₹913 crore from anchor investors, ahead of its initial share-sale opening for public subscription. INQ Holding LLC, SmallCap World Fund Inc, Fidelity Funds, Abu Dhabi Investment Authority, Goldman Sachs Funds, BlackRock ...
TPG Asia, HBM India to win big in Sai Life Sciences' upcoming IPO
5 天之前 · Sai Life Sciences reported revenue from operations of ₹ 1,465.1 crore in FY24, up from ₹ 1,217.1 crore a year earlier. Profit rose to ₹ 83 crore from ₹ 9 crore over the same period.
News & Events - Sai Life Sciences
Sai Life Sciences augments DMPK capabilities to ace large-scale collaborations. To offer global big pharma clients cutting-edge, end-to-end drug metabolism and pharmacokinetics (DMPK) services, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), has expanded its DMPK capabilities.
Sai Life Sciences - CDMOs, CRO, Contract research, development ...
Sai Life Sciences, the fastest-growing Indian Contract Research, Development and Manufacturing Organization (CRDMO) [1], announced that it has received Establishment Inspection Reports (EIR) from the US Food and Drug Administration (USFDA) for its R&D (Unit II, Hyderabad), and Manufacturing (Unit IV, Bidar) sites in India.
Sai Life Sciences enters its Silver Jubilee year; surpasses vision of ...
HYDERABAD, India, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), entered its Silver Jubilee year with...
Sai Life Sciences IPO Day 3: Check key dates, price band, GMP, …
1 天前 · Sai Life Sciences' Rs 3,042 crore IPO was oversubscribed 1.25 times on its second day, driven by institutional investors. The IPO, priced at Rs 522-549 per share, closes today. Proceeds will be used for debt repayment and general corporate purposes. Analysts remain neutral due to the offer's focus on OFS and high valuation.
- 某些结果已被删除